These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 22043044)

  • 21. Molecular class as a predictor of locoregional and distant recurrence in the neoadjuvant setting for breast cancer.
    Vargo JA; Beriwal S; Ahrendt GM; Soran A; Johnson RR; McGuire K; Bhargava R
    Oncology; 2011; 80(5-6):341-9. PubMed ID: 21791944
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neoadjuvant therapy as a platform for drug development and approval in breast cancer.
    Bardia A; Baselga J
    Clin Cancer Res; 2013 Dec; 19(23):6360-70. PubMed ID: 24298066
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response.
    de Ronde JJ; Hannemann J; Halfwerk H; Mulder L; Straver ME; Vrancken Peeters MJ; Wesseling J; van de Vijver M; Wessels LF; Rodenhuis S
    Breast Cancer Res Treat; 2010 Jan; 119(1):119-26. PubMed ID: 19669409
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy.
    Li X; Lewis MT; Huang J; Gutierrez C; Osborne CK; Wu MF; Hilsenbeck SG; Pavlick A; Zhang X; Chamness GC; Wong H; Rosen J; Chang JC
    J Natl Cancer Inst; 2008 May; 100(9):672-9. PubMed ID: 18445819
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Progression and treatment of HER2-positive breast cancer.
    Davoli A; Hocevar BA; Brown TL
    Cancer Chemother Pharmacol; 2010 Mar; 65(4):611-23. PubMed ID: 20087739
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Practice and consideration on neoadjuvant therapy for early breast cancer].
    Song ST
    Zhonghua Zhong Liu Za Zhi; 2010 Jul; 32(7):555-7. PubMed ID: 21029704
    [No Abstract]   [Full Text] [Related]  

  • 27. Relationship between hormonal receptors, HER-2, p53 protein, Bcl-2, and MIB-1 status and the antitumor effects of neoadjuvant anthracycline-based chemotherapy in invasive breast cancer patients.
    Kariya S; Ogawa Y; Nishioka A; Moriki T; Ohnishi T; Ito S; Murata Y; Yoshida S
    Radiat Med; 2005 May; 23(3):189-94. PubMed ID: 15940066
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
    Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
    J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lessons on responsiveness to adjuvant systemic therapies learned from the neoadjuvant setting.
    Colleoni M; Viale G; Goldhirsch A
    Breast; 2009 Oct; 18 Suppl 3():S137-40. PubMed ID: 19914533
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic and therapeutic implications of distinct kinase expression patterns in different subtypes of breast cancer.
    Bianchini G; Iwamoto T; Qi Y; Coutant C; Shiang CY; Wang B; Santarpia L; Valero V; Hortobagyi GN; Symmans WF; Gianni L; Pusztai L
    Cancer Res; 2010 Nov; 70(21):8852-62. PubMed ID: 20959472
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The effect of the microenvironment of head and neck cancers on tumor progression].
    Lukits J
    Magy Onkol; 2009 Mar; 53(1):51-9. PubMed ID: 19318327
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Surrogate markers for targeted therapy-based treatment activity and efficacy.
    Bianchini G; Gianni L
    J Natl Cancer Inst Monogr; 2011; 2011(43):91-4. PubMed ID: 22043050
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Search for new treatments intensifies for triple-negative breast cancer.
    Brower V
    J Natl Cancer Inst; 2009 Nov; 101(22):1536-7. PubMed ID: 19880812
    [No Abstract]   [Full Text] [Related]  

  • 34. Is triple negative a prognostic factor in breast cancer?
    Nishimura R; Arima N
    Breast Cancer; 2008; 15(4):303-8. PubMed ID: 18369692
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of ERalpha, PR and ERbeta isoforms in neoadjuvant treated breast cancer.
    Wurster M; Ruoff A; Meisner C; Seeger H; Vogel U; Juhasz-Böss I; Solomayer E; Wallwiener D; Fehm T; Neubauer H
    Oncol Rep; 2010 Sep; 24(3):653-9. PubMed ID: 20664970
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adjuvant chemotherapy for early-stage breast cancer.
    McArthur HL; Hudis CA
    Hematol Oncol Clin North Am; 2007 Apr; 21(2):207-22. PubMed ID: 17512445
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Accuracy of breast magnetic resonance imaging in predicting pathologic response in patients treated with neoadjuvant chemotherapy.
    De Los Santos J; Bernreuter W; Keene K; Krontiras H; Carpenter J; Bland K; Cantor A; Forero A
    Clin Breast Cancer; 2011 Oct; 11(5):312-9. PubMed ID: 21831721
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MicroRNA signatures: clinical biomarkers for the diagnosis and treatment of breast cancer.
    Andorfer CA; Necela BM; Thompson EA; Perez EA
    Trends Mol Med; 2011 Jun; 17(6):313-9. PubMed ID: 21376668
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New omics information for clinical trial utility in the primary setting.
    Damia G; Broggini M; Marsoni S; Venturini S; Generali D
    J Natl Cancer Inst Monogr; 2011; 2011(43):128-33. PubMed ID: 22043059
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Gene expression analysis and its clinical use in breast tumors].
    Semiglazov VF; Semiglazov VV; Moiseenko FV; Bogdanov AA; Boĭtsov VV; Viaz'min SV; Gorab DN; Chubenko VA; Brezhnev NV; Luk'ianchikova VS; Dubina MV
    Vopr Onkol; 2013; 59(1):25-9. PubMed ID: 23805447
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.